Key Takeaways Epidiolex now drives over a quarter of Jazz's product sales and is on track for blockbuster status.Jazz balances growth with a strong oncology and neuroscience portfolio beyond cannabis therapies.Acquisition of Chimerix added Modeyso, its sixth oncology drug, after FDA approval for certain gliomas.JAZZ Pharmaceuticals (JAZZ) is not your typical cannabis stock involved in cultivation, processing, or sales of marijuana products. Instead, this commercial-stage biotech is the only one to market an ...

In this article, we will be taking a look at the 10 Best Pharma Stocks to Buy According to Billionaires. Recently, President Trump wrote letters to 17 major pharmaceutical firms outlining the actions they should take to bring the prices of prescription pharmaceuticals in the United States down to “most favored nation” (MFN) levels by September 29.President Trump’s demand for “binding commitments” to lower drug prices sent pharmaceutical companies “scrambling to respond,” according to a CNBC report on August ...

核心观点 - Jazz Pharmaceuticals plc (JAZZ) 入选12只廉价医疗股榜单并排名第九[1] - 公司核心业务聚焦肿瘤学、神经科学和睡眠医学领域创新疗法开发与商业化[1] - 获得FDA加速批准新型口服药物Modeyso用于治疗罕见儿科脑肿瘤[2][3] - 通过管线多元化和战略扩展强化神经科学与肿瘤学领域布局[3] 产品管线进展 - Modeyso (dordaviprone) 于2025年8月6日获FDA加速批准，成为首款针对1岁以上H3 K27M突变型弥漫性中线胶质瘤患者的疗法[2][3] - 该药物针对美国年患者数约2000人的罕见脑癌群体，临床数据显示22%总体缓解率（50例患者），中位缓解持续时间达10.3个月[2] - 73%应答者维持反应超过6个月，采用每周口服胶囊给药方式[2] - 继续批准取决于正在进行的三期ACTION验证性试验结果[2] 研发战略布局 - 神经科学领域：授权引进临床前阶段癫痫药物SAN2355以强化产品组合[3] - 肿瘤学领域：推进zanidatamab三期研究用于晚期胃食管癌，同时寻求Zepzelca作为广泛期小细胞肺癌一线治疗的监管批准[3] 市场定位 - 公司被列为低成本医疗保健投资标的，专注于满足未满足医疗需求的复杂疾病领域[1] - 全球生物制药领导者地位通过多元化管线建设和战略扩展得以强化[1][3]